Department of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, 43205, USA.
Acta Neuropathol Commun. 2023 Jan 26;11(1):20. doi: 10.1186/s40478-023-01518-9.
Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy. The distinction between these disorders is therefore crucial when the diagnosis remains ambiguous after initial investigations. We sought to identify biomarkers facilitating this distinction and to investigate the pathophysiology of nemaline rod formation in these different disorders. Twenty-two muscle samples from patients affected by SLONM or iNM underwent quantitative histological analysis, laser capture microdissection for proteomic analysis of nemaline rod areas and rod-free areas, and transcriptomic analysis. In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples. In SLONM, muscle fibers harboring nemaline rods were smaller than those without rods. Necrotic fibers, increased endomysial connective tissue, and atrophic fibers filled with nemaline rods were more common in SLONM. Proteomic analysis detected differentially expressed proteins between nemaline rod areas and rod-free areas, as well as between SLONM and iNM. These differentially expressed proteins implicated immune, structural, metabolic, and cellular processes in disease pathophysiology. Notably, immunoglobulin overexpression with accumulation in nemaline rod areas was detected in SLONM. Transcriptomic analysis corroborated proteomic findings and further revealed substantial gene expression differences between SLONM and iNM. Overall, we identified unique pathological and molecular signatures associated with SLONM and iNM, suggesting distinct underlying pathophysiological mechanisms. These findings represent a step towards enhanced diagnostic tools and towards development of treatments for SLONM.
获得性散发性晚发性杆状体肌病 (SLONM) 和遗传性杆状体肌病 (iNM) 均表现为肌纤维中杆状体的积累。与 iNM 不同,SLONM 可接受治疗。因此,在初始检查后诊断仍不明确时,区分这些疾病至关重要。我们试图确定有助于区分这些疾病的生物标志物,并研究这些不同疾病中杆状体形成的病理生理学。22 例来自 SLONM 或 iNM 患者的肌肉样本接受了定量组织学分析、激光捕获显微切割以进行杆状体区域和无杆状体区域的蛋白质组学分析以及转录组学分析。在所有 iNM 样本中,杆状体均位于肌小节下或中央聚集体中,而在大多数 SLONM 样本中,杆状体则弥散分布于肌纤维内。在 SLONM 中,含有杆状体的肌纤维比不含杆状体的肌纤维小。坏死纤维、增加的内肌膜结缔组织和充满杆状体的萎缩纤维在 SLONM 中更为常见。蛋白质组学分析检测到杆状体区域和无杆状体区域之间以及 SLONM 和 iNM 之间的差异表达蛋白。这些差异表达蛋白提示免疫、结构、代谢和细胞过程参与疾病病理生理学。值得注意的是,在 SLONM 中检测到免疫球蛋白过度表达并在杆状体区域积累。转录组学分析证实了蛋白质组学发现,并进一步揭示了 SLONM 和 iNM 之间的大量基因表达差异。总体而言,我们确定了与 SLONM 和 iNM 相关的独特的病理和分子特征,提示存在不同的潜在病理生理学机制。这些发现代表了朝着增强诊断工具和开发 SLONM 治疗方法迈出的一步。
Acta Neuropathol Commun. 2023-1-26
Curr Neurol Neurosci Rep. 2023-11
Orphanet J Rare Dis. 2017-5-11
Ann Clin Transl Neurol. 2022-3
J Clin Neurosci. 2018-7
Muscle Nerve. 2013-10-28
Neurology. 2003-2-25
Intern Med. 2024-10-1
Acta Neuropathol Commun. 2022-12-17
Neurol Neuroimmunol Neuroinflamm. 2022-7
Ann Clin Transl Neurol. 2022-3
Neuromuscul Disord. 2021-10
Neurol Genet. 2021-5-18